Cellular Models and Therapeutic Perspectives in Hypertrophic Cardiomyopathy

Overview

Journal Med Genet

Publisher De Gruyter

Specialties Genetics
Medical Ethics

Date 2024 Jun 5

PMID 38835701

Authors

Gokhan Yigit

Bernd Wollnik

Affiliations

Soon will be listed here.

Abstract

Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous cardiac disease that is mainly characterized by left ventricular hypertrophy in the absence of any additional cardiac or systemic disease. HCM is genetically heterogeneous, inherited mainly in an autosomal dominant pattern, and so far pathogenic variants have been identified in more than 20 genes, mostly encoding proteins of the cardiac sarcomere. Based on its variable penetrance and expressivity, pathogenicity of newly identified variants often remains unsolved, underlining the importance of cellular and tissue-based models that help to uncover causative genetic alterations and, additionally, provide appropriate systems for the analysis of disease hallmarks as well as for the design and application of new therapeutic strategies like drug screenings and genome/base editing approaches. Here, we review the current state of cellular and tissue-engineered models and provide future perspectives for personalized therapeutic strategies of HCM.

References

Wang L, Kim K, Parikh S, Cadar A, Bersell K, He H . Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes. J Mol Cell Cardiol. 2017; 114:320-327. PMC: 5800960. DOI: 10.1016/j.yjmcc.2017.12.002. View

Ye L, Zimmermann W, Garry D, Zhang J . Patching the heart: cardiac repair from within and outside. Circ Res. 2013; 113(7):922-32. PMC: 3886802. DOI: 10.1161/CIRCRESAHA.113.300216. View

Tapia N, Scholer H . Molecular Obstacles to Clinical Translation of iPSCs. Cell Stem Cell. 2016; 19(3):298-309. DOI: 10.1016/j.stem.2016.06.017. View

Nunes S, Miklas J, Liu J, Aschar-Sobbi R, Xiao Y, Zhang B . Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods. 2013; 10(8):781-7. PMC: 4071061. DOI: 10.1038/nmeth.2524. View

Bhagwan J, Mosqueira D, Chairez-Cantu K, Mannhardt I, Bodbin S, Bakar M . Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics. J Mol Cell Cardiol. 2020; 145:43-53. PMC: 7487780. DOI: 10.1016/j.yjmcc.2020.06.003. View

Olson T, Karst M, Whitby F, Driscoll D . Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. Circulation. 2002; 105(20):2337-40. DOI: 10.1161/01.cir.0000018444.47798.94. View

Ma N, Zhang J, Itzhaki I, Zhang S, Chen H, Haddad F . Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells. Circulation. 2018; 138(23):2666-2681. PMC: 6298866. DOI: 10.1161/CIRCULATIONAHA.117.032273. View

Jang Y, Choi S, Lim D, Kim J, Kim J, Park Y . Modulating cardiomyocyte and fibroblast interaction using layer-by-layer deposition facilitates synchronisation of cardiac macro tissues. Soft Matter. 2019; 16(2):428-434. DOI: 10.1039/c9sm01531k. View

Josowitz R, Mulero-Navarro S, Rodriguez N, Falce C, Cohen N, Ullian E . Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes. Stem Cell Reports. 2016; 7(3):355-369. PMC: 5032183. DOI: 10.1016/j.stemcr.2016.07.018. View

10.

Zhang D, Shadrin I, Lam J, Xian H, Snodgrass H, Bursac N . Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials. 2013; 34(23):5813-20. PMC: 3660435. DOI: 10.1016/j.biomaterials.2013.04.026. View

11.

Varnava A, Elliott P, Sharma S, McKenna W, Davies M . Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000; 84(5):476-82. PMC: 1729476. DOI: 10.1136/heart.84.5.476. View

12.

Prondzynski M, Kramer E, Laufer S, Shibamiya A, Pless O, Flenner F . Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes. Mol Ther Nucleic Acids. 2017; 7:475-486. PMC: 5458066. DOI: 10.1016/j.omtn.2017.05.008. View

13.

van den Berg C, Okawa S, Chuva de Sousa Lopes S, Van Iperen L, Passier R, Braam S . Transcriptome of human foetal heart compared with cardiomyocytes from pluripotent stem cells. Development. 2015; 142(18):3231-8. DOI: 10.1242/dev.123810. View

14.

Mummery C, Zhang J, Ng E, Elliott D, Elefanty A, Kamp T . Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res. 2012; 111(3):344-58. PMC: 3578601. DOI: 10.1161/CIRCRESAHA.110.227512. View

15.

Lu T, Lin B, Kim J, Sullivan M, Tobita K, Salama G . Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells. Nat Commun. 2013; 4:2307. DOI: 10.1038/ncomms3307. View

16.

Vander Roest A, Liu C, Morck M, Kooiker K, Jung G, Song D . Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state. Proc Natl Acad Sci U S A. 2021; 118(24). PMC: 8214707. DOI: 10.1073/pnas.2025030118. View

17.

Daily N, Yin Y, Kemanli P, Ip B, Wakatsuki T . Improving Cardiac Action Potential Measurements: 2D and 3D Cell Culture. J Bioeng Biomed Sci. 2017; 5(3). PMC: 5404700. DOI: 10.4172/2155-9538.1000168. View

18.

Carvajal-Vergara X, Sevilla A, DSouza S, Ang Y, Schaniel C, Lee D . Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010; 465(7299):808-12. PMC: 2885001. DOI: 10.1038/nature09005. View

19.

Birket M, Ribeiro M, Kosmidis G, Ward D, Leitoguinho A, van de Pol V . Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function. Cell Rep. 2015; 13(4):733-745. PMC: 4644234. DOI: 10.1016/j.celrep.2015.09.025. View

20.

Mills R, Parker B, Quaife-Ryan G, Voges H, Needham E, Bornot A . Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway. Cell Stem Cell. 2019; 24(6):895-907.e6. DOI: 10.1016/j.stem.2019.03.009. View